Today we’re pleased to announce a new partnership with Boehringer Ingelheim!
Through this partnership, Boehringer Ingelheim will leverage our natural product discovery capabilities. The goal is to accelerate their discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs.
Hundreds of millions of people are living with diseases that to date cannot be cured or are inadequately treated. Breaking through this inertia requires, in many cases, the use of new techniques to act on molecular targets which are exceedingly difficult to address with traditional approaches.
Boehringer Ingelheim will utilize our metagenomic sequence database. This provides access to a vast reservoir of structurally novel bioactive molecules.This access can potentially enable the rapid identification of lead molecules as starting points for the potential discovery of novel treatments to transform patients’ lives.
Unlocking new possibilities in biopharma innovation
We are well-positioned to help partners like Boehringer Ingelheim complement their drug discovery efforts, particularly when it comes to natural product discovery.
We’ve built one of the broadest and deepest metagenomics databases worldwide, aided by our recent acquisition of Zymergen. The database comprises over three terabases of sequence data and over two billion proprietary protein sequences from a variety of microbes. This creates a unique foundation for the discovery of novel therapeutic molecules.
Find the full press release here along with all of the latest news from the Ginkgo team.
What will you grow with Ginkgo?